Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBenchmark Holdings Regulatory News (BMK)

Share Price Information for Benchmark Holdings (BMK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 43.20
Bid: 44.10
Ask: 45.90
Change: -0.50 (-1.10%)
Spread: 1.80 (4.082%)
Open: 43.00
High: 43.20
Low: 43.00
Prev. Close: 45.50
BMK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update and Notice of Results

25 May 2017 07:00

RNS Number : 1690G
Benchmark Holdings PLC
25 May 2017
 

 

Benchmark Holdings PLC

25 May 2017

 

Benchmark Holdings plc("Benchmark", the "Company" or the "Group")

Trading Update and Notice of Results

Benchmark, the aquaculture biotechnology and food chain sustainability business, announces that Group performance for the six months to 31 March 2017 was broadly in line with the Board's expectations.

Highlights of the first half year include:

· Benchmark signed a joint venture agreement with SalMar ASA, through which it will provide genetics, health and knowledge services to the world's third largest salmon producer. This is an important acknowledgement of Benchmark's technology, and exemplifies its strategy to provide a suite of technology solutions to the aquaculture industry.

· Construction of the Group's new salmon egg production facility in Norway continued on schedule. This important development will underpin Benchmark Breeding and Genetics' market leading position in the sector.

· Good progress was made in Advanced Animal Nutrition towards the goal of delivering 100% live replacement for feeding juvenile shrimp, a key to unlocking future growth potential for the industry.

· As anticipated, the Animal Health division saw significantly lower demand for Salmosan in Norway due to an industry focus on new solutions to the significant sea lice challenge.

· Good progress was made towards the commercial field trials launch of a ground-breaking sea lice treatment. Significant revenues from this product are anticipated in H2 and beyond, which are projected to support achievement of the Board's expectations for FY 2017 following the challenging first half for Salmosan.

· The new state-of-the-art vaccine manufacturing facility in Braintree is being commissioned and first commercial batches are expected in H2.

 

In the shrimp sector, disease challenge coupled with low market prices resulted in delayed sector investment and lower growth rates in the first half year. The Group has proceeded cautiously with new investments, whilst continuing to progress core infrastructure projects which support long term growth.

The Group is seeking to grow sales and market share in developing markets, including China, for its Breeding and Genetics and Advanced Animal Nutrition Divisions, and is progressing towards establishing strategic relationships in those regions. Further progress has been made with the development of the Group-wide customer account management programme, which will promote the full benefit of Benchmark's integrated technology solutions in aquaculture.

The long term drivers of growth in the Company's sectors, which include the growing global demand for aquaculture products and an ever increasing pressure to limit the use of antibiotics in the food chain, remain strong, with increasing momentum and interest in the aquaculture market. The Company continues to focus on delivery of its strategy to deploy leading technologies drawn from across the Group, through established distribution channels, into long-term growth markets.

Benchmark expects to announce its interim results for the six months to 31 March 2017 during the week commencing 26 June 2017.

 

Commenting on trading, Benchmark's Chief Executive Officer, Malcolm Pye, said: 

"The agreement with SalMar is an example of the value we can deliver to our customers by aggregating leading technologies to provide integrated solutions to the issues faced by the food production industry. There are a number of technologies in the later stages of development that we are particularly excited about, and we look forward to delivering these, through our distribution networks, including into the significant Asian and Latin American shrimp and tilapia markets."

 

-Ends-

 

 

For further information, please contact:

 

Benchmark Holdings plc

 Tel: 020 7920 3150

 Malcolm Pye, CEO

 Roland Bonney, COO

 Rachel Aninakwah, Communications

 

Numis

 Tel: 020 7260 1000

 Michael Meade / Freddie Barnfield (NOMAD)

 James Black (Corporate Broking)

 

Tavistock

 Tel: 020 7920 3150

 Niall Walsh / Simon Hudson

 

 

Notes to Editors:

 

Benchmark challenges the status quo in aquaculture, agriculture and animal healthcare.

Since 2000, Benchmark has consistently worked to build a platform to serve its customers, helping farmers to take control of their biological environment through the combination of genetics, nutrition, health and knowledge services. Through its in-depth knowledge of animal biology Benchmark is able to tackle the key issues in the aquaculture, livestock and companion animal sectors.

The Company has proven distribution capabilities in high growth markets and operates internationally with R&D facilities, commercial farms, diagnostic laboratories, manufacturing sites, production facilities and commercial offices across 27 countries in five continents. As at 28 February 2017, Benchmark employed 900 people.

For further information on Benchmark please visit www.benchmarkplc.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTLLFVDEVISFID
Date   Source Headline
21st Jun 20214:41 pmRNSSecond Price Monitoring Extn
21st Jun 20214:36 pmRNSPrice Monitoring Extension
2nd Jun 20214:41 pmRNSSecond Price Monitoring Extn
2nd Jun 20214:35 pmRNSPrice Monitoring Extension
28th May 20217:00 amRNSTotal Voting Rights
25th May 20217:00 amRNSDirector Dealings
18th May 20217:00 amRNSSecond Quarter and Interim results
30th Apr 20217:00 amRNSTotal Voting Rights
19th Apr 20217:00 amRNSNotice of Q2 and Interim Results
16th Apr 202111:00 amRNSBMK08+CleanTreat Update
31st Mar 20213:41 pmRNSDirector Dealings
31st Mar 20217:00 amRNSTotal Voting Rights
30th Mar 20217:00 amRNSListing of existing senior secured NOK bond
26th Mar 20218:24 amRNSBMK08+CleanTreat Update
19th Mar 20217:00 amRNSBLOCK LISTING SIX MONTHLY RETURN
26th Feb 202110:52 amRNSTotal Voting Rights
22nd Feb 20217:00 amRNSQ1 Results
9th Feb 202112:43 pmRNSResult of AGM
9th Feb 20217:00 amRNSNotice of Q1 Results
29th Jan 20217:00 amRNSTotal Voting Rights
13th Jan 20217:00 amRNSIssue of Equity
8th Jan 20211:13 pmRNSReplacement: DIRECTOR SHARE OPTIONS
8th Jan 20219:57 amRNSDIRECTOR SHARE OPTIONS
6th Jan 20213:45 pmRNSDirector Dealings
31st Dec 20207:00 amRNSTotal Voting Rights
11th Dec 20205:32 pmRNSPosting of Annual Report and Notice of AGM
2nd Dec 20202:09 pmRNSDirector Dealings
1st Dec 20204:02 pmRNSAnnual Financial Report
1st Dec 202011:30 amRNSDirector Dealings
1st Dec 202010:30 amRNSDirector Dealings
1st Dec 202010:21 amRNSPCA Dealing
30th Nov 20207:00 amRNSTotal Voting Rights
27th Nov 20207:00 amRNSQ4 Results
27th Nov 20207:00 amRNSFull Year Results
18th Nov 20207:00 amRNSDirectorate Change
4th Nov 20207:00 amRNSInvestor Presentation for Retail Investors
30th Oct 20207:00 amRNSTotal Voting Rights
27th Oct 20207:00 amRNSNotice of Results
13th Oct 20202:29 pmRNSHolding(s) in Company
12th Oct 20202:50 pmRNSHolding(s) in Company
30th Sep 20207:00 amRNSTotal Voting Rights
29th Sep 20207:00 amRNSHolding(s) in Company
21st Sep 20207:00 amRNSBLOCK LISTING SIX MONTHLY RETURN
11th Sep 20205:58 pmRNSHolding(s) in Company
10th Sep 20209:15 amRNSPositive Opinion from the EMA on BMK08
4th Sep 20207:00 amRNSDirector/PDMR Shareholding
28th Aug 20207:00 amRNSTotal Voting Rights
28th Aug 20207:00 amRNSQ3 Results
21st Aug 20207:00 amRNSNotice of Q3 Results
31st Jul 202011:17 amRNSCompletion of sale of vaccine facility

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.